Notably, a p53 DBD-derived peptide harboring the aggregation-suppressing I254R mutation (denoted ReACp53; Fig. 1c) was shown to block mutant p53 aggregation by masking the aggregation-prone core, which restored the mutant protein to a WT p53-like functionality and reduced cancer cell proliferation in vitro and halted tumor progression in vivo14. The gene discussed is TP53; the disease is neoplasm.